Eva Poveda López-rekin lankidetzan egindako argitalpenak (23)

2019

  1. Clinical presentation of individuals with human T-cell leukemia virus type-1 infection in Spain

    Open Forum Infectious Diseases, Vol. 6, Núm. 2

  2. HTLV testing of solid organ transplant donors

    Clinical Transplantation

  3. HTLV-1 infection in solid organ transplant donors and recipients in Spain

    BMC Infectious Diseases, Vol. 19, Núm. 1

2017

  1. Human T-lymphotropic virus type 1 infection and disease in Spain

    AIDS, Vol. 31, Núm. 12, pp. 1653-1663

2015

  1. Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 104.e1-104.e5

  2. Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012)

    Clinical Microbiology and Infection, Vol. 21, Núm. 1, pp. 105.e1-105.e5

2013

  1. Hepatitis B in HIV-infected patients

    Clinics in Liver Disease, Vol. 17, Núm. 3, pp. 489-501

  2. Hepatitis C therapy with HCV NS5B polymerase inhibitors

    Expert Opinion on Pharmacotherapy, Vol. 14, Núm. 9, pp. 1161-1170

  3. Hepatitis C therapy: Highlights from the 2012 annual meeting of the european association for the study of the liver

    Clinical Infectious Diseases, Vol. 56, Núm. 4, pp. 560-566

  4. Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B

    AIDS, Vol. 27, Núm. 14, pp. 2219-2224

  5. Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy

    Journal of Clinical Virology, Vol. 58, Núm. 2, pp. 391-395

  6. Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in Spain

    Liver International, Vol. 33, Núm. 9, pp. 1357-1362

  7. The changing face of hepatitis C in the new era of direct-acting antivirals

    Antiviral Research

  8. Very late relapse after discontinuation of antiviral therapy for chronic hepatitis C

    Antiviral Therapy, Vol. 18, Núm. 8, pp. 1033-1035

2012

  1. Pharmacogenetics of hepatitis C

    Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 3, pp. 523-529

  2. Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain

    Antiviral Therapy, Vol. 17, Núm. 3, pp. 571-575

  3. Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor

    Antiviral Therapy, Vol. 17, Núm. 5, pp. 921-926

  4. Treatment failure with new hepatitis C drugs

    Expert Opinion on Pharmacotherapy, Vol. 13, Núm. 3, pp. 313-323

2011

  1. Directly acting antivirals against hepatitis C virus

    Journal of Antimicrobial Chemotherapy, Vol. 66, Núm. 8, pp. 1673-1686

2009

  1. Raltegravir and etravirine are active against HIV Type 1 group O

    AIDS Research and Human Retroviruses, Vol. 25, Núm. 2, pp. 225-227